Navigation Links
Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results
Date:8/14/2008

une 30

2008 2007 2008 2007

As Adjusted As Adjusted

(Note1) (Note 1)

REVENUE - RELATED

PARTIES $ 19,654,447 $ 14,320,482 $ 32,475,268 $30,557,271

COST OF SALES -

RELATED PARTIES 6,203,705 4,454,594 10,243,765 8,890,193

GROSS PROFIT 13,450,742 9,865,888 22,231,503 21,667,078

SELLING, GENERAL AND

ADMINISTRATIVE

EXPENSES 5,088,597 3,388,675 8,335,796 6,653,582

INCOME FROM

OPERATIONS 8,362,145 6,477,213 13,895,707 15,013,496

(Interest

expense) (80,078) (106,351) (132,662) (211,573)

Interest income 268,517 587,270 505,849 1,217,183

Other (expense), net (1,246,287) (42,984) (986,864) (117,463)

OTHER (EXPENSE),

INCOME, NET (1,057,848) 437,935 (613,677) 888,147

INCOME BEFORE

PROVISION FOR INCOME

TAXES AND MINORITY

INTEREST 7,304,297 6,915,148 13,282,030 15,901,643

PROVISION FOR

INCOME TAXES 1,664,054 555,395 3,144,448 1,266,405

INCOME BEFORE

MINORITY INTEREST 5,640,243 6,359,753 10,137,582 14,635,238

MINORITY INTEREST 998,642 1,369,361 1,887,079 3,122,579

NET INCOME 4,641,601 4,990,392 8,250,503 11,512,659

OTHER COMPREHENSIVE

INCOME

Foreign currency

translation

adjustment 2,675,768 2,383,905 7,099,628 3,773,257

COMPREHENSIVE

INCOME $ 7,317,369 $ 7,374,297 $ 15,350,131 $15,285,916

EARNINGS PER SHARE,

BASIC AND DILUTED $ 0.07 $ 0.07 $ 0.12 $ 0.16

'/>"/>
SOURCE Tiens Biotech Group (USA), Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. eFuture Signs Contract to Provide Tiens Group with Retail Business Management System
2. Tiens Biotech Group (USA) Reports Fourth Quarter and Twelve-Month Results
3. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results
4. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
5. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
6. ThirdBiotech Announces Kemeta as Newest Sponsor
7. Yongye Biotechnology International Retains CCG Investor Relations
8. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
9. Mark C. Mirken Named New CEO and Chairman of the Board of Millennium Biotechnologies, Inc.
10. Ortho Biotech Announces Nationwide Voluntary Recall of Procrit(R) (Epoetin Alfa) Lot Number P114942A
11. New Book on the Business of Biotechnology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... (PRWEB) December 15, 2014 METTLER ... inline PVM tool, ParticleView V19 with PVM ... situ probe-based particle vision and measurement tool continuously ... process conditions. ParticleView V19 then automatically prepares a ... tracking particle size and concentration changes. This compelling ...
(Date:12/15/2014)... , Dec. 15, 2014  Ascendis Pharma A/S, ... technology to address significant unmet medical needs, today ... Phase 2 pediatric study to evaluate once-weekly TransCon ... or GHD.  This interim analysis consists of 25 ... enrollment in the study, completing all six months ...
(Date:12/13/2014)... 12, 2014 Trend lines for photonics ... global economic growth, Eugene Arthurs, CEO of SPIE, ... in a featured talk at OPTIC (Optics and Photonics ... National Chung Hsing University in Taichung. , As examples, ... future energy supplies and soon to hit US$50 billion ...
(Date:12/13/2014)... , Dec. 11, 2014 Research and ... the addition of the "Glucose Sensors: the ... http://photos.prnewswire.com/prnh/20130307/600769 ... product designs is giving hope for a better ... glucose monitors that can measure glucose levels accurately ...
Breaking Biology Technology:New Real-Time In Situ Probe-Based Video Microscope from METTLER TOLEDO 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 2Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 3Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 4Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 5Glucose Sensors: the Next Generation 2Glucose Sensors: the Next Generation 3
... 2 More than a dozen internationally renowned speakers, ... team, will be coming to New Haven, CT to ... symposium taking place March 23-24, 2009.The roster includes scientists ... creation of two new human embryonic stem cell lines ...
... Cephalon, Inc .,(Nasdaq: CEPH ) today ... worldwide rights to Lupuzor(TM), an investigational medication for the,treatment ... of the ImmuPharma Phase IIb study. Cephalon will assume ... commercialization of,the product. , ImmuPharma ...
... BioMed Realty Trust, Inc. (NYSE: BMR ) ... and year ended December 31, 2008 after the market closes ... Chief Executive Officer, and Kent Griffin, President and Chief Financial ... Pacific Time on Thursday, February 12, 2009 to discuss the ...
Cached Biology Technology:Obama Advisor Joins Connecticut and International Scientists at New Haven Stem Cell Symposium 2Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor 2Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor 3Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor 4Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor 5BioMed Realty Trust to Report 2008 Fourth Quarter and Year-End Results 2
(Date:12/5/2014)... Calif. , Dec. 4, 2014 ... has boosted investments in new testing and inspection ... also given rise to a range of innovative ... the requirements of Generation Y, which is generally ... As a result, product development strategies of test ...
(Date:11/21/2014)... According to a new market research report ... Control, Intrusion Detection, Parking Management, Under Vehicle Inspection), End ... - Global Forecasts to 2020", published by MarketsandMarkets, The ... $25 Billion in 2014 and is expected to reach ... 8.69%. Browse 116 market data Tables and ...
(Date:11/18/2014)... 18, 2014  The Secure Identity & Biometrics ... jointly announce the formation of The Airport Entry ... Identity and Biometric Entry and Exit Solutions ... official support from BORDERPOL, the international non-profit organization ... provide expertise regarding border security, traveler and migration ...
Breaking Biology News(10 mins):Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3
... Institute near Cambridge, supported by the Alzheimer,s Research ... Council (BBSRC), have discovered that the brain,s circuitry ... ageing such as Alzheimer,s disease. The findings were ... Alzheimer,s disease causes nerve cells in the ...
... The Stowers Institute,s Linheng Li Lab has identified the precise ... were published today in the Advance Online Publication of ... of the Institute,s support facilities to develop a new technology ... to monitor the dynamic behavior of stem cells. This technology ...
... NY, December 4, 2008Researchers are taking a closer look ... to demonstrate that inhibiting this biological route suppresses tumor ... ( GEN ). The pathway is involved in angiogenesis, ... part of the PI3/AKT/mTOR pathway, which plays a key ...
Cached Biology News:Maintaining the brain's wiring in aging and disease 2Stowers Institute's Linheng Li Lab expands understanding of bone marrow stem cell niche 2
Human Legumain Affinity Purified Polyclonal Ab...
Human Cystatin F MAb (Clone 292103)...
... Ac-DEVD-CHO is an inhibitor ... The concentration of inhibitor ... activity must be determined ... Ten micromolar inhibitor is ...
Human RELT/TNFRSF19L Affinity Purified Polyclonal Ab...
Biology Products: